Overview
Influenza is a contagious respiratory disease caused by influenza viruses that can result in hospitalization and, in extreme cases, death. Humans are infected by the influenza virus, which infects the respiratory tract (nostrils, mouth, and airways). Seasonal influenza is a virus that may be found all year, although it is more frequent during the influenza season, especially in the fall and winter months. Influenza infection is present at a low level throughout the year in diverse geographical locations, although it displays a seasonal rise during the winter months.
A seasonal influenza flu vaccination helps to reduce the risk of contracting seasonal flu and to keep it from spreading all year. Repeated influenza infections are caused by influenza viruses’ great diversity and extensive host specificity. Vaccine-induced virus neutralizing antibodies are strain specific, which need annual vaccination updates. To address this problem, a number of government and commercial research groups are working to create new vaccinations that will improve the efficacy of existing vaccines.
Get a Sample Copy of the Seasonal Influenza Vaccines market Report 2021
Drivers
The rising prevalence of seasonal influenza infection in different parts of the world is projected to be a significant driver of the global seasonal influenza vaccines market. Growing influenza pandemics and their intensity, which can be related to the virus’s genetic variety, are another element driving the industry forward. Additionally, the Centers for Medicare & Medicaid Services (CMS) reimburses 100% of the cost of one seasonal influenza viral vaccination every influenza season, as well as the seasonal influenza virus immunizations.
As a result, favorable reimbursement is projected to have a beneficial impact on seasonal influenza vaccine uptake rates, boosting the global seasonal influenza vaccines market development.
Various government agencies, such as the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), have collaborated with the business sector to produce better influenza vaccinations in the United States. As a result, the country’s influenza pandemic preparation has improved.
In order to enhance the availability of influenza vaccinations, many government entities in the United States are focused on cooperation. In April 2018, the Bill and Melinda Gates Foundation announced a $12 million grant for the development of universal influenza vaccines. The funding is designed to encourage the development of new treatments for influenza pandemics. The global seasonal influenza vaccines market is projected to rise due to increased government and private sector activities in the United States.
Ask for PDF sample copy of the Seasonal Influenza Vaccines market report
The influenza flu vaccine helps to lower the risk of flu-related hospitalization in both adults and children. According to the Centers for Disease Control and Prevention, flu vaccines averted 1.9 million flu infections, 966,000 flu-related routine check-ups, and 67,000 flu-related hospitalizations in the United States in 2015, a reduction of 6.5 percent in disease burden.
Infections with the seasonal influenza virus have the potential to cause considerable death and morbidity across the world. Furthermore, modern influenza virus vaccinations provide an efficient antiviral defense against infection. Growing intergenic diversity among influenza virus strains, on the other hand, has increased the need for influenza vaccinations that are compatible with all kinds of influenza virus. The National Institute of Allergy and Infectious Diseases is working on an influenza vaccine for people of all ages that will protect them from a variety of influenza strains, including those that might create a pandemic. Seqirus began commercial production of a cell-based influenza vaccine in June 2017, utilizing a candidate vaccine virus (CVVs) that had been identified and cultured in cells rather than virus CVVs generated from eggs.
Restraints
The global seasonal influenza vaccines market is being held back by high manufacturing costs and a complicated manufacturing process due to the intrinsic diversity of virus strains. Seasonal influenza vaccinations are difficult to produce due to the sluggish egg-based production technique currently in use.
Regional Insights
Due to increased research and development studies by major market participants to produce innovative influenza vaccines and the rising incidence of seasonal influenza illness in the area, North America dominates the global seasonal influenza vaccines market. Over the projection period, Asia Pacific is predicted to expand at the quickest rate. This is attributable to a big patient pool and leading market participants’ increased focus on expanding in this region. According to the World Health Organization, an estimated 4.74 million new cases of tuberculosis were recorded in 2015, with an estimated 8,00,000 individuals dying from tuberculosis and tuberculosis and HIV co-infection (TB-HIV) in the South-East.
Competitive Landscape
Major companies contributing in the global seasonal influenza vaccines market are Medimmune, LLC, Sanofi S.A., CSL Limited, and GlaxoSmithKline Plc.
Sanofi Pasteur purchased Protein Sciences Corporation in August 2017, gaining access to Flublok products, the only FDA-approved recombinant protein-based influenza vaccine. Sanofi’s influenza vaccine portfolio and position in the global vaccines market were both extended as a result of the purchase.
Reasons to Purchase this Report
• To gain an in-depth understanding of Seasonal Influenza Vaccines market globally
• To identify the on-going trends and anticipated growth in the next nine years
• To help industry consultants, Seasonal Influenza Vaccines market other stakeholders align their market-centric strategies
• To obtain research-based business decisions and add weight to presentations and marketing strategies
• To gain competitive knowledge of leading market players
Buy This Complete A Business Report With Flat US $2000 Off
Table of Content
Global Seasonal Influenza Vaccines Market Research Report
Section 1: Global Seasonal Influenza Vaccines Industry Overview
Section 2: Global Economic Impact on Seasonal Influenza Vaccines Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Seasonal Influenza Vaccines Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Seasonal Influenza Vaccines Market Forecast
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837